NeRRe Therapeutics, is pleased to announce the appointment of Dr Steve Pawsey as Chief Medical Officer. Dr Pawsey, an anaesthetist by training, has extensive experience in the global pharmaceutical and biotechnology sector, having worked in clinical development roles for over 20 years. He will lead the progress of NeRRe’s two lead NK receptor antagonists, orvepitant and NT-814, towards late-stage clinical development, for which activity an oversubscribed £23m fundraising was recently announced.
Dr Pawsey’s biotechnology company experience includes senior development roles at UK companies Circassia, Vernalis and Pharmagene. He began his industry career working at Upjohn, Abbott Laboratories and Roche. He holds a medical degree from the University of London and is a Fellow of both the Faculty of Pharmaceutical Medicine and the Royal College of Anaesthetists.
‘Steve brings to NeRRe Therapeutics a wealth of clinical development experience gained over many years in the pharmaceutical and biotechnology industry’, said Dr Mary Kerr, the company’s CEO. ‘Having just completed our £23m Series B fundraising for pipeline development, it is a great time to welcome him to the team.’
Dr Steve Pawsey, NeRRe’s CMO, said, ‘It is tremendously exciting to be joining the company as it accelerates development of its two lead products, for chronic refractory cough and post-menopausal vasomotor symptoms. These are debilitating conditions for thousands of patients worldwide, and NeRRe is working to provide solutions in these areas of unmet medical need.’